A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4 ...
Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued ...
Read the latest healthcare, biotech, and pharmaceutical stock news and analysis. Uncover the latest research and company analysis to empower your investments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results